Drug industry group disputes lowering cost-effectiveness thresholds

01/30/2013 | PharmaTimes (U.K.)

Lowering the current threshold of quality-adjusted life years, or QALYs, for assessing the cost effectiveness of new drugs and medicines would deny such medications to thousands and lead to a decline in U.K. health standards, according to the Association of the British Pharmaceutical Industry. The group was responding to a study by University of York health economists who said the current standard "is not based on evidence" and should be reduced.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Behavioral Health Operations
Meridian Health Plan
Detroit, MI
Medical Director
PacificSource
Bend, OR
Clinical Appeals RN
MJHS
Brooklyn, NY
Director of Clinical Operations
Meridian Health Plan
Detroit, MI
Sr. Director, Regulatory Compliance Intelligence and Outreach
Johnson & Johnson
New Brunswick, NJ